Abstract
Diabetes impairs fracture healing. In diabetic mice, we found that PGC‐1α expression is downregulated in bone marrow mesenchymal stem cell (BMSC). PGC‐1α levels positively correlate with osteogenic capacity. Physiologically, reduced PGC‐1α suppresses miR‐363‐3p expression; mechanistically, this further inhibits DKK3, thereby promoting β‐catenin phosphorylation and degradation, which in turn inhibits osteogenesis in BMSCs. To target this pathway, we treated BMSC with calcium silicate (CaSiO 3 ). CaSiO 3 inhibited the ubiquitination‐mediated degradation of PGC‐1α, restoring miR‐363‐3p expression. It also upregulated AGO2, which facilitated the assembly of miR‐363‐3p into mi‐RISC complexes and their loading into extracellular vesicles. We then engineered a ROS‐responsive hydrogel (Gel ROS ) to deliver these CaSiO 3 ‐engineered extracellular vesicles (EVs). In diabetic mice with femoral fractures, the hydrogel enabled sustained, on‐demand release of EVs specifically at sites with high ROS levels. The released EVs, enriched with miRISC complexes, suppressed the DKK3‐β‐catenin axis in recipient BMSC, enhanced osteogenesis, and accelerated fracture healing. This study identifies the PGC‐1α–miR‐363‐3p–DKK3‐β–catenin axis as a key pathway in diabetic fracture healing. It also presents a novel EVs‐based strategy that avoids direct CaSiO 3 toxicity, offering a new translational approach for treating diabetic bone defects.
Funding Information
  • National Natural Science Foundation of China (82272491)
  • National Natural Science Foundation of China (82472438)

This publication has 25 references indexed in Scilit: